Key statistics dashboard for Biomea Fusion, Inc. (BMEA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; an...
Stock Data
| Price | $1.74 |
| Market Cap | $126M |
| Beta | -0.27 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -3.53 |
| Price / Book | 10.43 |
| P/S | 0.00 |
| P/FCF | -2.69 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 3.47 |
| Quick Ratio | 3.47 |
| Cash Ratio | 3.32 |
| Debt / Equity | 0.07 |
| Debt / Assets | 2.38% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -13.01 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.17 |
| Cash per share | 0.48 |
| FCF per share | -0.65 |
| Tangible Book Value per share | 0.17 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 10 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 13 |
| Avg rating (1-5) | 0.77 |
Related companies: ADVM · ALXO · CAMP · CBUS · GUTS · IMUX · PMVP
Explore sector: Healthcare · Biotechnology
More sections of BMEA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks